home>imcbc>staff_doc>pub>hofmann.html Seite teilen:

Johann Hofmann, Ph.D., Retired

Publications:

1. Hofmann, J. Cellulase-, xylanase-, pectinase-activities and microbial biomass determinations in soils. Thesis, University of Innsbruck, 1979.

2. Schinner, F., and Hofmann, J. Cellulase, xylanase and pectinase actvity of different soils of the upper subalpine zone. In: Ökologische Analysen von Almflächen im Gasteiner Tal. Universitätsverlag Wagner, Innsbruck, 289-298, 1978

3. Hofmann, J., and Pfitscher, A. Correlations of enzyme-activities in soil. Z. Pflanzenernaehr. Bodenk. 145, 36-41, 1982

4. Hofmann, J., and Pfitscher, A. Changing of microbial activities in alpine soils under ski slopes and foot pathes. Pedobiologia, 23, 105-111, 1982

5. Moser, M., Hofmann, J., Pfitscher, A., Ridl, W., and Wieser, R. Mikrobielle Parameter als Indikatoren für die anthropogene Beeinflussung alpiner Böden, besonders durch Massentourismus. In: MaB-Projekt Obergurgl, Universitätsverlag Wagner, 10, 257-279, 1987.

6. Schinner, F., Hofmann, J., and Niederbacher, R. Mikrobielle Aktivitäten des Kohlenstoffmetabolismus in Böden der alpinen, subalpinen und montanen Stufe des Grossglocknergebietes (Hohe Tauern). In: Struktur und Funktion von Graslandökosystemen im Nationalpark Hohe Tauern, Österr. Akademie der Wissenschaften, Universitätsverlag Innsbruck, 257-262, 1989.

7. Klocker, H., Auer, B,. Burtscher, H.J., Hofmann, J., Hirsch-Kauffmann, M., and Schweiger, M. A sensitive radioimmuno assay for thymine dimers. Mol. Gen. Genet. 186, 475-477, 198

8. Grunicke, H., Doppler, W., Finch, S.A.E., Greinert, R.,Grünewald, K., Hofmann, J., Maly, K., Stier, A., Scheidl, F., and Thomas, J.K. Effects of nitrogen mustard on potassium transport systems and membrane structure of Ehrlich ascites tumor cells. Adv. Enzyme Regul., 23, 277-290, 1985

9. Doppler, W., Hofmann, J., Oberhuber, H., Maly, K., and Grunicke, H. Nitrogen mustard interference with potassium transport systems in Ehrlich ascites tumor cells. J. Cancer Res. Clin. Oncol. 110, 35-41, 1985

10. Doppler, W., Maly, K., Hofmann, J., and Grunicke, H. Inhibition of tumor cell growth by interference with growth factor induced cell proliferation. Cell Membranes and Cancer, 343-346, T. Galeotti et al. editors, Elsevier Science Publishers, 1985

11. Grunicke, H., Doppler, W., Hofmann, J., Lindner, H., Maly, K.,Oberhuber, H., Ringsdorf, H., and Roberts, J.J. Plasma membrane as target of alkylating agents. Adv. Enzyme Regul., 24, 247-261, 1986

12. Grunicke, H., Helliger, W., Hermann, B. J., Höck, W., Hofmann, J., and Puschendorf, B. Alkylating antitumor agents reduce histone acetyl-transferase activity. Adv. Enzyme Regul., 25, 87-97, 1986

13. Grunicke, H., Doppler, W., Hofmann, J., Lindner, H., Maly, K., Oberhuber, H., Puschendorf, B., and Ringsdorf, H. New strategies of improvement of alkylating antitumor agents. Cancer Biology and Therapeutics. (J.G. Cory and A. Szentivanyi, eds.) 127-129, Plenum Publishing Corporation, 1986

14. Grunicke, H., Doppler, W., Helliger, W., Hermann, B.J., Hofmann, J., Lindner, H., and Puschendorf, B. Progress in tumorchemotherapy based on advances in tumorbiochemistry. Arch. Geschwulstforsch. 56, 3, 183-191, 1986

15. Doppler, W., Hofmann, J., Maly, K., and Grunicke, H. Amiloride and 5-N,N-dimethylamiloride inhibit the carrier mediated uptake of choline and N-mustard in Ehrlich ascites tumor cells. Biochem. Pharmacol., 36, 1645-1649, 1987

16. Doppler, W., Hofmann, J., Maly, K., and Grunicke, H. Protection of Ehrlich ascites tumor cells against the antiproliferative effect of mechlorethamine (nitrogen mustard) by 5-N,N-dimethylamiloride. Cancer Res., 48, 2454-2457, 1988

17. Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Überall, F., and Grunicke, H. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42, 382-388, 1988

18. Maly, K., Doppler, W., Oberhuber, H., Meusburger, H., Hofmann, J., Jaggi, R., and Grunicke, H. Desensitization of the Ca-mobilizing system to serum growth factors by Ha-ras and v-mos. Mol. Cell. Biol., 8, 4212-4216, 1988

19. Helliger, W., Hofmann, J., Maly, K., Doppler, W., Hermann, B.-J., Höck, W., Puschendorf, B., and Grunicke, H. Differential sensitivity of histone acetylation in nitrogen-mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand crosslinks. Eur. J. Cancer Clin. Oncol., 24, 1861-1868, 1988

20. Hofmann, J., Überall, F., Posch, L., Maly, K., Herrmann, D. B. J., and Grunicke H. Synergistic enhancement of the anti-proliferative activity of cis-diamminedichloro-platinum(II) by the new ether lipid analogue BM 41 440, an inhibitor of protein kinase C. Lipids, 24, 312-317, 1989

21. Grunicke, H., Hofmann, J., Maly, K., Überall, F., Posch, L., Fiebig, H., Yamada, Y., Natsumeda, Y., Helliger, W., Schletterer, C., Talasz, H., Weiss, G., Puschendorf, B., and Weber, G. Nuclear components and plasma membrane as targets of chemotherapeutic agents. In: Cancer Therapy, New Trends (P. Bannasch, ed.) 120-126, Springer Verlag, Berlin, Heidelberg, 1989

22. Grunicke, H., Hofmann, J., Maly, K., Überall, F., Posch, L., Oberhuber, H., and Fiebig, H. The phospholipid- and calcium-dependent protein kinase as a target in tumor chemotherapy. Adv. Enzyme Regul., 28, 201-216, 1989

23. Hofmann, J., Fiebig, H. H., Winterhalter, B. R., Berger, D. P., and Grunicke, H. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int. J. Cancer, 45, 536-539, 1990

24. Hofmann, J., Überall, F., Egle, A., and Grunicke, H. B-859-35, a new drug with antitumor activity reverses multidrug resistance. Int. J. Cancer, 47, 870-874, 1991

25. Ludescher C., Gattringer, C., Drach, J., Hofmann, J., and Grunicke, H. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. Blood, 78, 1385-1387, 1991

26. Überall, F., Maly, K., Egle, A., Doppler, W., Hofmann J. and Grunicke, H. Inhibition of cell proliferation, protein kinase C and phorbol ester-induced fos-expression by the dihydropyridine derivative B859-35. Cancer Res., 51, 5821-5825, 1991

27. Grunicke, H.H., Hofmann, J., Maly, K., Oberhuber, H., Überall, F., Egle, A., and Demuth, L. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and other antitumor agents by inhibitors of enzymes involved in growth factor signal-transduction. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, S.B. Howell, ed. Plenum Press, New York, 161-172. 1991

28. Hofmann, J., Wolf, A., Spitaler, M., Überall, F., Herrmann, D.B.J., and Grunicke, H. The new anticancer drug ilmofosine enhances the activity of cis-platin and reverses multidrug resistance. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. (S. Nigam, K.V. Honn, L.J. Marnett, and T.L. Walden, Jr., eds.) Kluwer Publishers, Boston, 603-605, 1992.

29. Hofmann, J., Wolf, A., Spitaler, M., Böck, G., Drach, J., Ludescher, C., and Grunicke, H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol., 118, 361-366, 1992.

30. Ludescher, C., Thaler, J., Drach, D., Drach, J., Spitaler, M., Gattringer, C., Huber, H., and Hofmann, J. Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123. Brit. J. Haematol., 82, 1, 161-169, 1992

31. Grunicke, H., and Hofmann, J. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Therap., 55, 1-30, 1992

32. Ludescher, C., Hilbe, W., Eisterer, W., Preuß, E., Huber, C., Gotwald, M., Hofmann, J., and Thaler, J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst., 85, 1751-1758, 1993

33. Hofmann, J., Ludescher, C., Böck, G., Spitaler, M., Wolf, A., Grunicke, H., and Thaler, J. Detection of P-glycoprotein activity in tissue culture and clinical samples using the fluorescent dye rhodamine 123. In: The Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma. The Clinical Value of Laboratory Studies. G.J.L Kaspers, R. Pieters, P.R. Twentyman, L.M. Weisenthal and A.J.P. Veerman, eds.Harwood Academic Publishers, 131-140, 1993.

34. Ludescher, C., Hilbe, W., Eisterer, W., Thaler, J., Gotwald, M., and Hofmann, J. Low incidence of activity of P-glycoprotein (P-170) in de novo acute lymphoblastic leukemia determined by a flow cytometric assay. Blood, 82, 3505-3506, 1993

35. Grunicke, H., Hofmann, J., Utz, I. and Überall, F. Role of protein kinases in antitumor drug resistance. Ann. of Hematology, 69, S1-S6, 1994.

36. Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., and Hofmann, J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57, 104-110, 1994.

37. Hofmann, J., O´Connor, P.M., Jackman, J., Schubert, C., Ueberall, F., Kohn, K.W., and Grunicke, H. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem. Biophys. Res. Comm., 199, 2, 937-943, 1994.

38. Ludescher, C., Hilbe, W., Eisterer, W., Preuß, E., Hofmann, J., and Thaler, J. Funktionelle Erfassung P-Glykoprotein-exprimierender Zellen mittels Durchflußzytometrie. Wiener Klin. Wochenschr., 106/8, 242-246, 1994.

39. Hofmann, J., Gekeler, V., Ise, W., Noller, A., Mitterdorfer, J., Hofer, S., Utz, I., Gotwald, M., Boer, R., Glossmann, H., and Grunicke, H. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol., 49, 603-609, 1995.

40. Ludescher, C., Eisterer, W., Hilbe, W., Gotwald, M., Hofmann, J., Cianfriglia, M., and Thaler. J. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia, 9, 350-356, 1995.

41. Ludescher, D., Eisterer, W., Hilbe, W., Hofmann, J., and Thaler, J. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Brit. J. Haematol., 91, 652-657, 1995.

42. Hofmann, J., and Ludescher, C. Multiple Resistenz gegen Zytostatika. Berichte der ÖGKC, 18, 153-157, 1995.

43. Utz, I., Gekeler, V., Ise, W., Beck, J., Spitaler, M., Grunicke, H., and Hofmann J. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res., 16, 289-296, 1996.

44. Gekeler, V., Boer, R., Überall, F., Ise, W., Schubert, C., Utz, I., Hofmann, J., Sanders, K.H., Schächtele, C., Klemm, K., and Grunicke, H. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein mediated multidrug resistance. Brit. J. Cancer, 74, 897-905, 1996.

45. Easmon, J., Heinisch, G., Hofmann, J., Langer, T., Grunicke, H.H., Fink, J., and Pürstinger, G. Thiazoyl and benzothiazoyl hydrazones derived from -(N)-acetylpyridines and diazines: synthesis, antiproliferative activity, and CoMFA studies. Eur. J. Med. Chem., 32, 397-408, 1997

46. Hofmann, J. The potential for isoenzyme-specific inibition of protein kinase C. FASEB J., 11, 649-669, 1997

47. Hofmann, J., Utz, I., Spitaler, M., Hofer, S., Rybczynska, M., Beck, W.T., Herrmann, D.B.J., and Grunicke, H. Resistance to the new anticancer phospholipid ilmofosine (BM 41 440). Brit. J. Cancer, 76, 862-869, 1997

48. Pall, G., Spitaler, M., Hofmann, J., Thaler, J., and Ludescher, C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia, 11, 1067-1072, 1997

49. Easmon, J., Heinisch, G., Pürstinger, G., Langer, T., Österreicher, J.K., Grunicke, H.H., and Hofmann, J. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity. J. Med. Chem., 40, 4420-4425, 1997

50. Utz, I., Spitaler, M., Rybczynska, M., Ludescher, C., Hilbe, W., Regenass, U., Grunicke, H., and Hofmann, J. Reversal of multidrug resistance by the staurosporine-derivatives CGP 41251 and CGP 42700. Int. J. Cancer, 77, 64-69, 1998

51. Spitaler, M., Utz, I., Hilbe, W., Hofmann, J., and Grunicke, H.H. PKC-independent modulation of multi-drug resistance in cells expressing mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin. Biochem. Pharmacol., 56, 861-869, 1998

52. Jenny, M., Easmon, J., Puerstinger, G., Heinisch, G., and Hofmann, J. Screening of new potential ribonucleotide reductase inhibitors in tissue culture. In: Relevance of Tumor Models in Anticancer Drug Development. Contrib. Oncol. Basel, Karger, Vol. 54, 409-417, 1999

53. Spitaler, M., Wiesenhofer, B., Biedermann, V., Seppi, T., Zimmermann, J., Grunicke, H.,

and Hofmann, J. The involvement of protein kinase C isoenzymes ,  and  in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res., 19, 3969-3976, 1999

54. Hofmann, J. In vitro assays to predict the efficacy of new antitumor drugs and chemosensitizers. In: Research without Animal Experiments 2000. Schröffl H., Spielmann H, Tritthart H. A. (eds), Springer Verlag Vienna, New York, 185-193, 2000

55. Hofmann, J. Protein Kinase C und Resistenzmodulation. Hämato-Onkologische Nachrichten, Medcon, 10, 4, 2000

56. Hofmann, J. Modulation of Protein Kinase C in Antitumor Treatment. Rev. Physiol. Biochem. Pharmacol., 142, 1-96, 2001

57. Easmon, J., Pürstinger, G., Heinisch, G., Roth, T., Fiebig, H.H., Holzer, W., Jäger, W., Jenny, M., and Hofmann J. Synthesis, cytotoxicity, and antitumor activity of Copper(II) and Iron(II) complexes of N-azabicyclo[3,2,2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem., 44, 2164-2171, 2001

58. Conseil, G., Perez-Victoria, J.M., Jault, J.-M., Gamarro, F., Goffeau, A., Hofmann, J., and Di Pietro, A. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry, 40, 2564-2571, 2001

59. Hofmann J. Protein Kinase C und die Modulation der Multidrug Resistenz. Symp. Med. Oncol., 12, 12-13, 2001

60. Rybczynska, M., Liu, R., Lu, P., Sharom, F.J., Steinfels, E., Pietro, A.D., Spitaler, M., Grunicke, H., and Hofmann, J. MDR1 and MRP cause resistance to the antitumor drug miltefosine. Brit. J. Cancer, 84, 10, 1405-1411, 2001

61. Rybczynska, M., Spitaler, M., Knebel, N. G., Böck, G., Grunicke, H., and Hofmann, J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol., 62, 765-772, 2001

62. Easmon, J., Puerstinger, G., Roth, T., Fiebig, H.H., Jenny, M., Jaeger, W., Heinisch, G., and Hofmann, J. 2-Benzoxazolyl- and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: a novel class of antitumor agents. Int. J. Cancer, 94, 89-96, 2001

63. Mwanjewe, J, Spitaler, M., Ebner, M., Windegger, M., Geiger, M., Kampfer, S., Hofmann, J., Uberall, F., and Grunicke, H.H. Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota. Biochem. J., 359, 211-217, 2001

64. Hofmann, J. Protein kinase C isozymes as potential targets for anticancer therapy. Current Cancer Drug Targets, 4, 125-146, 2004.

65. Margesin, R., Dieplinger, H., Hofmann, J., Sarg, B., and H. Lindner. A cold-active extracellular metalloprotease from Pedobacter cryoconitis – production and properties. Res. Microbiol., 156, 499-505, 2005

66. Shishkin A. A, Ivanov O. G., Zaitsev A. V., Kononova E. G., Malinina E. A., Ol'shevskaya V. A., Kalinin V. N., Hofmann J., Shtil A. A. The copper-containing monocarboranylporphyrin: a prototype of new DNA-binding cytotoxic compounds. Dokl. Biochem. Biophys., 403, 313-316. 2005

67. Ol’shevskaya, V.A., Zaitsev, A.V., Luzgina, V.N., Kondratieva, T.T., Ivanov, O.G., Kononova, E.G., Petrovskii, P.V., Mironov, A.F., Kalinin, V.N., Hofmann, J., and Shtil, A.A. Novel boronated derivatives of 5,10,15,20-tetraphenylporphyrin: synthesis and toxicity for anticancer drug resistant tumor cells. Bioorg. Med. Chem., 14, 109-120, 2006.

68. Garczarczyk, D., Rechfeld, F., Hechenberger, G., and Hofmann, J. Protein kinase C isozymes – targets for potential therapies. DOSIS, 22, 93-103, 2006

69. Easmon, J., Pürstinger, G., Thies, K, Heinisch, G. and Hofmann, J. Synthesis, structure activity-relationships and antitumor studies of 2-benzoxazolyl hydrazones derived from -(N)-acyl heteroaromatics. J. Med. Chem., 49, 6343-6350, 2006

70. Lamy, C., Hofmann, J., Parrot-Lopez, H., and Goekjian, P. Synthesis of a fluoroalkene peptidomimetic precursor of N-acetyl-L-glutamyl-L-alanine. Tetrahedron Lett., 48, 6177-6180, 2007

71. Perkhofer, S., Kehrel, B.E., Dierich, M.P., Donnelly, J.P., Nussbaumer, W., Hofmann, J., von Eiff, C., Lass-Florl, C. Human platelets attenuate Aspergillus species via granule-dependent mechanisms. J. Infect Dis., 198, 1243-1246, 2008

72. Hofmann, J. Resistance to chemotherapy. Brit. J. Cancer, 99, 1368, 2008

73. Hofmann, J., Easmon, J., Pürstinger, G., Heinisch, G., Condorelli, D. F., Musumarra, G., Jenny, M., Shtil, A., and Scire, S. Investigations on the mechanism of action of the new antitumor compound EPH136. Invest. New Drugs, 27, 189-202, 2009

74. Garczarczyk, D., Toton, E., Biedermann, V., Rosivatz, E., Rechfeld, F., Rybczynska, M., and Hofmann, J. Signal transduction of constitutively active protein kinase C epsilon. Cell Signal., 21, 745–752, 2009

75. Radford, D.J. Wang, K., McNelis, J.C., Taylor, A.E., Hechenberger, G., Hofmann, J., Chahal, H., Arlt, W., and Lord, J.M. Dehdyroepiandrosterone Sulfate Directly Activates Protein Kinase C- to Increase Human Neutrophil Superoxide Generation. Mol. Endocrinol. 24, 813-821, 2010

76. Garczarczyk, D., Szeker, K., Galfi, P., Csordas, A., and Hofmann J. Protein kinase Cγ in colon cancer cells: Expression, Thr514 phophorylation and sensitivity to butyrate-mediated upregulation as related to the degree of differentiation. Chem. Biol. Interact. 185, 25-32, 2010.

77. Gruber, P., Rechfeld, F., Kirchmair, J., Hauser, N., Boehler, M., Garczarczyk, D., Langer, T., Hofmann, J. Barbituric acid derivative BAS 02104951 inhibits PKCε, PKCη, KCε/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKCε and η translocation in PC3 cells ollowing TPA-induction. J. Biochem. 149, 331-336, 2011

78. Rechfeld, F., Gruber, P., Hofmann, J., and Kirchmair, J. Modulators of protein-protein interactions – novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. Curr. Top. Med. Chem. 11, 1305-1319, 2011

79. Paszel, A., Blazej Rubis, B., Barbara Bednarczyk-Cwynar, B., Lucjusz Zaprutko, L., Mariusz Kaczmarek, M., Johann Hofmann, J., and Maria Rybczynska, M. The oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-oate targets multidrug resistance related to ABCB1. Pharmacol. Rep. 63, 1500-1517, 2012

80. Toton, E., Lisiak, N., Rubis, B., Budzianowski, J., Gruber, P., Hofmann, J., and Rybczynska, M. The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease. Eur. J. Pharmacol. 682, 21-28, 2012

81. Rubis, B., Holysz, H., Gladych, M., Toton, E., Paszel, A., Lisiak, N., Kaczmarek, M., Hofmann, J., Rybczynska, M. Telomerase downregulation induces proapoptotic genes expression and initializes breast cancer cells apoptosis followed by DNA fragmentation in a cell type dependent manner. Mol. Biol. Rep. 40, 4995-5004, 2013

82. Rechfeld, F., Gruber, P., Kirchmair, J., Boehler, M., Hauser, N., Hechenberger, G., Garczarczyk, D., Lapa, G. B., Preobrazhenskaya, M. N., Goekjian, P., Langer, T., Hofmann, J. Thienoquinolines as Novel Disruptors of the PKCε/RACK2 Protein-Protein Interaction. J. Med. Chem. 57, 3235-3246, 2014

83. Easmon, J., Pürstinger, G., Heinisch, G., Fiebig, H. H, Roth, T., Hofmann, J. Synthesis, cytotoxic, and antitumor activities of 2-pyridylhydrazones derived from 3-benzoylpyridazines. Arch. Pharm. 347, 599-608, 2014